Author: Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Title: Network-based Drug Repurposing for Human Coronavirus Document date: 2020_2_5
ID: b4mdiont_91
Snippet: We first collected three differential gene expression data sets of hosts infected by HCoVs from the NCBI Gene Expression Omnibus (GEO). Among them, two transcriptome data sets were SARS-CoV infected samples from patient's peripheral blood [88] (GSE1739) and Calu-3 cells [89] (GSE33267) respectively. One transcriptome data set was MERS-CoV infected Calu-3 cells [90] (GSE122876). Adjusted P value less than 0.01 was defined as differentially express.....
Document: We first collected three differential gene expression data sets of hosts infected by HCoVs from the NCBI Gene Expression Omnibus (GEO). Among them, two transcriptome data sets were SARS-CoV infected samples from patient's peripheral blood [88] (GSE1739) and Calu-3 cells [89] (GSE33267) respectively. One transcriptome data set was MERS-CoV infected Calu-3 cells [90] (GSE122876). Adjusted P value less than 0.01 was defined as differentially expressed genes. These data sets were used as HCoV host signatures to evaluate the treatment effects of drugs. Differential gene expression in cells treated with various drugs were retrieved from the Connectivity Map (CMAP) database [33] , and were used as gene profiles for the drugs. For each drug that was in both the CMAP data set and our drug-target network, we calculated an enrichment score (ES) for each HCoV signature data set based on previously described methods [91] as follows:
Search related documents:
Co phrase search for related documents- CMAP database and enrichment score: 1
- CMAP database and ES enrichment score: 1
- data set and drug target: 1, 2, 3, 4, 5, 6
- data set and drug treat: 1, 2
- data set and enrichment score: 1
- data set and ES enrichment score: 1
Co phrase search for related documents, hyperlinks ordered by date